

**HAPPY NEW YEAR**

**Jafron Monthly**

NO. 17  
 December, 2021

## Jafron e-Seminar: Walking with the Luminaries Webinars Review in 2021

**In 2021, we invited more than 30 experts to give lectures or share experiences on Jafronclub. Following are the highlights of our 20+ Webinars last year:**

- Apr. 22 Development of extracorporeal blood purification therapies: focus on adsorption
- Apr. 30 Haemoadsorption therapy in septic patients
- May. 13 Hemoperfusion on COVID-19 patients - experience sharing
- May. 27 Operation - HP+CRRT - everyday issue
- Jun. 10 Hemoperfusion on critical illness - experience sharing  
The role of hemoperfusion in COVID-19
- Jun. 25 Adsorption therapy – on the way from the concept to bedside hemoperfusion by HA330 for sepsis and acute pancreatitis
- Jun. 26 Hemoperfusion therapy in COVID-19: principle and practical experience
- Jul. 16 Theoretical and experience sharing of organ support therapy and hemoperfusion for sepsis/serious burn/cardiac surgery patients
- Jul. 16 The role of hemoperfusion - organ support therapy and hemoperfusion for intensive care
- Jul. 29 The development of extracorporeal therapy for liver failure patients
- Aug. 5 Hemoperfusion in sepsis – current evidence and practice
- Aug. 19 RCT Announcement: the primary results of RCT of HA230 hemoperfusion on organophosphorus poisoning
- Aug. 26 Round table discussion on hemoperfusion on COVID-19
- Sep. 17 Hemoperfusion in cardiac surgery
- Sep. 28 What have we learned and what should we do about hemoperfusion on critical patients?
- Nov. 8 Webinar of the year: The task of hemoadsorption therapies in practice

Great thanks to all experts and healthcare providers for their contributions and educational progress in the clinical applications of hemoperfusion products and therapies.

Until December 20, there are 4400+ medical colleagues from over 100 countries registered on [jafronclub.com](http://jafronclub.com). Welcome to join us!

## News & Events

### Jafron won the Championship in the Individual Manufacturing Industry authorized by MIIT in China.

The Chinese Ministry of Industry and Information Technology(MIIT) announced the latest list of Championship in the Individual Manufacturing Industry on November 8th, 2021. Jafron was awarded as one of the top enterprises on the list, which represents the top-tier position in the field of hemoperfusion industry.



### Jafron "CA330", the first Cytokine Adsorption Column specialized in septic patients in China, was launched and successfully applied.



On December 10th, 2021, the CA330 column was launched and applied by the Intensivist of China-Japan Friendship Hospital in Beijing to successfully treat the patient with septic shock. After completion of adsorption therapy with one CA330 cartridge, the patient's IL-6 dropped from 9740µg/L to 213µg/L! Congratulations to the first clinical application of the Jafron Cytokine Adsorption Column in China.

### Jafron initiated the operation of the 3rd manufacturing base

Jafron continues expanding its infrastructure in China. On Dec 6th, a new manufacturing base in Hubei that will contribute a dialysate production capacity for 20M therapies per year was put into operation.



### A New Year Greeting from Jafron.

Jafron wishes you and your family all the happiness and good luck. 2022 is also the Chinese Year of the Tiger with ambition and courage. We look forward to working with you for the successful year 2022.